Figure 3.
Pharmacokinetics of rondoraptivon pegol. Pharmacokinetics of rondoraptivon pegol after subcutaneous injections in patients with type 2B VWD. Rondoraptivon pegol was given as 3 mg on days 0, 4, and 7, followed by weekly doses of 6 or 9 mg (only in patients with thrombocytopenia at baseline). The solid line with the stars indicates the median.